解读使用重定位药物达里芬素B的Cathepsin B的治疗向
Sayantani Mukhopadhyay1, Thirukumaran Kandasamy2, Siddhartha S Ghosh1
1IIT Guwahati: Indian Institute of Technology Guwahati, BSBE, INDIA.
ChemMedChem
|May 20, 2025
概括
达里芬素作为一种重定向药物,在癌症中向甲素B (CTSB) 的药物显示出希望. 这项研究发现,它有效地抑制CTSB,诱导癌细胞死亡,并减少神经母细胞瘤和乳腺癌模型中的瘤进展标志物.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 甲素,特别是甲素B (CTSB),是涉及癌症进展的溶酶蛋白酶.
- CTSB在乳腺癌和神经母细胞瘤的发展中发挥着重要作用.
研究的目的:
- 调查达里芬素作为潜在的针对CTSB的重用治疗剂.
- 评估达里芬素对癌细胞的分子机制和细胞毒性作用.
主要方法:
- 分子对接和模拟研究,以评估与CTSB的结合亲和力.
- 在神经母细胞瘤 (IMR-32) 和乳腺癌 (MCF-7) 细胞系上进行了体外细胞毒性测试 (IC50测定).
- 对细胞内活性氧物种 (ROS) 生成,线粒体膜潜力,细胞循环停止和亡诱导的分析.
- 评估达里芬素对脂质滴积累,细胞迁移和殖民地/球体形成的影响.
主要成果:
- 达里芬素对CTSB的结合能量明显低于已知的抑制剂阿洛克西斯丁.
- 达里芬素对IMR-32和MCF-7细胞具有细胞毒性疗效,IC50值分别为38.14μM和39.96μM.
- 达里芬素抑制CTSB活动导致ROS增加,线粒体脱极化,细胞循环停止和细胞亡 (IMR-32中的51.39%,MCF-7中的40.6%).
- 达里芬素还抑制了脂质滴积累,细胞迁移和殖民地/球体形成.
结论:
- 达里芬素被确定为CTSB的强有力的抑制剂.
- 达里芬素通过诱导亡和抑制关键癌症进展途径,表现出显著的抗癌特性.
- 达里芬素是CTSB驱动癌症的有希望的治疗候选者,包括神经母细胞瘤和乳腺癌.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
124
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
124
Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


